Kura Oncology, Inc. 4

Kura Oncology President and CEO Troy Edward Wilson bought 100,000 shares of KURA common stock on 2026-08-24 at an average price of $12.39, totaling about $1.24 million.

On August 24, 2026, Troy Edward Wilson, President and CEO of Kura Oncology, Inc., purchased 100,000 shares of Kura common stock in the open market at a weighted average price of $12.39 per share, for a total cost of approximately $1.24 million. The trades were executed in multiple lots at prices ranging from $11.47 to $12.85, and the transaction increased his indirectly held position in Kura common stock, held through the One Fish Two Fish Revocable Trust, to 479,194 shares. In addition, the Form 4 reflects 300,000 shares held indirectly by the Lorax Charitable Remainder Unitrust and 435,456 shares held directly, indicating substantial ongoing ownership alignment with shareholders following this significant insider purchase.

Filing Facts

CIK

1422143

Ticker

KURA

Form

4

Source Type

fda

Accession

0001193125-26-363812

Alert Tier

8